Published in Urology on October 01, 2003
Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54
Effects of local anesthetic concentration and dose on continuous interscalene nerve blocks: a dual-center, randomized, observer-masked, controlled study. Reg Anesth Pain Med (2009) 2.26
Symptom recovery after thoracic surgery: Measuring patient-reported outcomes with the MD Anderson Symptom Inventory. J Thorac Cardiovasc Surg (2015) 2.12
Predictive indices of morbidity and mortality after liver resection. Ann Surg (2006) 2.01
A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index. Br J Cancer (2005) 1.44
Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study. J Korean Med Sci (2017) 1.06
Treatment and survival differences in older Medicare patients with lung cancer as compared with those who are dually eligible for Medicare and Medicaid. J Clin Oncol (2008) 1.05
A meta-analysis of the predictive accuracy of postoperative mortality using the American Society of Anesthesiologists' physical status classification system. World J Surg (2015) 0.83
Correlations between age, Charlson score and outcome in clinical unilateral T3a prostate cancer. Asian J Androl (2008) 0.77
Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis. J Cancer Epidemiol (2012) 0.76
Comorbidity and nutritional indices as predictors of morbidity after transurethral procedures: A prospective cohort study. Can Urol Assoc J (2014) 0.76
Mortality Prediction in a Vertebral Compression Fracture Population: the ASA Physical Status Score versus the Charlson Comorbidity Index. Int J Spine Surg (2015) 0.75
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int (2006) 3.39
Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology (2013) 2.99
Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One (2008) 2.46
Primary closure techniques in chronic pilonidal sinus: a survey of the results of different surgical approaches. Dis Colon Rectum (2002) 2.17
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol (2012) 2.15
CARD15 genotype and phenotype analysis in 55 pediatric patients with Crohn disease from Saxony, Germany. J Pediatr Gastroenterol Nutr (2003) 2.11
Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study. BJU Int (2013) 2.08
Second cancers as competing causes of death after radical prostatectomy. J Urol (2009) 2.02
Evaluation of a diabetes management system based on practice guidelines, integrated care, and continuous quality management in a Federal State of Germany: a population-based approach to health care research. Diabetes Care (2008) 2.00
Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int (2008) 1.83
Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res (2003) 1.83
Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate (2006) 1.74
Advances in specific immunotherapy for prostate cancer. Eur Urol (2007) 1.70
Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol (2010) 1.57
Places of death from cancer in a rural location. Onkologie (2007) 1.47
Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit Care Med (2006) 1.46
Reliability of the Modified Tardieu Scale and the Modified Ashworth Scale in adult patients with severe brain injury: a comparison study. Clin Rehabil (2005) 1.44
Evaluation of dose-volume histograms after prostate seed implantation. 4-year experience. Strahlenther Onkol (2004) 1.44
Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases. Can J Urol (2012) 1.43
Dynamic contour tonometry in comparison to intracameral IOP measurements. Invest Ophthalmol Vis Sci (2008) 1.41
Expression of Ki-67 in squamous cell carcinoma of the penis. BJU Int (2005) 1.39
Risk-adjusted intraventricular hemorrhage rates in very premature infants: towards quality assurance between neonatal units. Dtsch Arztebl Int (2012) 1.39
Quantitative multi-gene expression profiling of primary prostate cancer. Prostate (2006) 1.36
Perioperative complications of radical cystectomy in a contemporary series. Eur Urol (2006) 1.35
External validation of a model to predict locoregional failure after radical cystectomy. Cancer (2014) 1.34
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol (2007) 1.34
Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia (2008) 1.32
A systematic review and meta-analysis of the effects of clinical pathways on length of stay, hospital costs and patient outcomes. BMC Health Serv Res (2008) 1.26
Is surgery for multiple lung metastases reasonable? A total of 328 consecutive patients with multiple-laser metastasectomies with a new 1318-nm Nd:YAG laser. J Thorac Cardiovasc Surg (2006) 1.25
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 1.21
Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol (2005) 1.14
Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs. BMC Cancer (2014) 1.12
[Acute psychiatric day hospital treatment: is the effectiveness of this treatment approach still questionable?]. Psychiatr Prax (2004) 1.10
What really matters is rarely measured: outcome of routine care and patient-reported outcomes. Eur Urol (2013) 1.09
Charlson score and competing mortality. Cancer (2014) 1.09
Incidence of childhood diabetes in children aged less than 15 years and its clinical and metabolic characteristics at the time of diagnosis: data from the Childhood Diabetes Registry of Saxony, Germany. Horm Res Paediatr (2010) 1.08
[On the efficacy of acute psychiatric day-care treatment in a one-year-follow-up. A comparison to inpatient treatment within a randomised controlled trial]. Psychiatr Prax (2006) 1.08
Socio-economic deprivation and cancer survival in Germany. Int J Cancer (2014) 1.07
Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int J Cancer (2009) 1.07
Comorbidity and mortality after brachytherapy: in regard to Nanda et al. Int J Radiat Oncol Biol Phys (2013) 1.07
Effect of age, tumor risk, and comorbidity in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 1.06
Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int (2006) 1.06
Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol (2010) 1.05
Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. J Urol (2002) 1.05
One-lung ventilation with high tidal volumes and zero positive end-expiratory pressure is injurious in the isolated rabbit lung model. Anesth Analg (2003) 1.05
siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol (2004) 1.03
Laser resection technique and results of multiple lung metastasectomies using a new 1,318 nm Nd:YAG laser system. Lasers Surg Med (2006) 1.02
Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int J Oncol (2003) 1.01
Which patients are at the highest risk of dying from competing causes ≤ 10 years after radical prostatectomy? BJU Int (2011) 1.00
Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol (2003) 0.99
Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol. Int J Oncol (2002) 0.99
Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer (2002) 0.98
Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS One (2013) 0.97
Impact factor for ranking academic urologic institutions. Eur Urol (2011) 0.96
Contribution of Ca2+ influx to carbachol-induced detrusor contraction is different in human urinary bladder compared to pig and mouse. Eur J Pharmacol (2007) 0.96
The influence of contractures and variation in measurement stretching velocity on the reliability of the Modified Ashworth Scale in patients with severe brain injury. Clin Rehabil (2005) 0.94
CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases. Int J Cancer (2012) 0.94
Catecholamines relax detrusor through beta 2-adrenoceptors in mouse and beta 3-adrenoceptors in man. J Pharmacol Exp Ther (2008) 0.94
Microarray analyses in bladder cancer cells: inhibition of hTERT expression down-regulates EGFR. Int J Cancer (2006) 0.94
Cholinergic and purinergic responses in isolated human detrusor in relation to age. J Urol (2005) 0.94
Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. J Cell Biochem (2011) 0.93
Interaction between age and comorbidity as predictors of mortality after radical prostatectomy. J Urol (2008) 0.93
Autoantibodies to thyroperoxidase (TPOAb) in a large population of euthyroid subjects: implications for the definition of TPOAb reference intervals. Clin Lab (2003) 0.93
Superglue in the Urethra: Surgical Treatment. Urol Int (2014) 0.93
Detection of circulating tumor cells from renal carcinoma patients: experiences of a two-center study. Oncol Rep (2005) 0.91
Systematic assessment of complications and outcome of radical cystectomy undertaken with curative intent in patients with comorbidity and over 75 years of age. Urol Int (2013) 0.90
Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. Int J Oncol (2012) 0.90
Significance of testicular microlithiasis. Urol Int (2005) 0.90
Risk factors for incidental prostate cancer-who should not undergo vaporization of the prostate for benign prostate hyperplasia? Prostate (2011) 0.90
Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. Prostate (2003) 0.90
Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. Br J Pharmacol (2005) 0.88
Utility of measuring vitamin B12 and its active fraction, holotranscobalamin, in neurological vitamin B12 deficiency syndromes. J Neurol (2010) 0.88
Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer. Biol Chem (2010) 0.88
Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis. Urology (2009) 0.88
Lobe-sparing resection of multiple pulmonary metastases with a new 1318-nm Nd:YAG laser--first 100 patients. Ann Thorac Surg (2002) 0.88
Oral health related quality of life and its association with sociodemographic and clinical findings in 3 northern outreach clinics. J Can Dent Assoc (2007) 0.87
Clinical parameters influencing the accuracy of 1- and 2-stage impressions: a randomized controlled trial. Int J Prosthodont (2008) 0.87
A combined index to classify prognostic comorbidity in candidates for radical prostatectomy. BMC Urol (2014) 0.87
Radical cystectomy in patients over 70 years of age: impact of comorbidity on perioperative morbidity and mortality. World J Urol (2011) 0.87
Feasibility and limitations of comorbidity measurement in patients undergoing radical prostatectomy. Eur Urol (2005) 0.86